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2. RESEARCH PROPOSAL: BILIARY ATRESIA AT RED CROSS WAR MEMORIAL CHILDREN’S 
HOSPITAL 
 
Biliary Atresia at Red Cross War Memorial Children’s Hospital: A retrospective descriptive 
study reviewing the age of presentation, clinical course and outcome of infants presenting to 
RCWMCH with biliary atresia.  
INVESTIGATORS 
Lindsey Levin (LVNLIN001), Elizabeth Goddard (Supervisor), Ronalda De Lacy (Co-supervisor), 
Komala Pillay (Co-supervisor, histology aspect) 
BACKGROUND 
Biliary atresia is a progressive obstructive cholangiopathy of unknown aetiology, occurring during the 
perinatal period. If left untreated it progresses to liver fibrosis and cirrhosis in the first few months of 
life, with death occurring in the first few years (1). It is the leading cause of end-stage liver disease in 
the paediatric population and remains the most common indication for liver transplantation in children 
(2). The current surgical management of biliary atresia involves hepatic portoenterostomy (Kasai 
procedure) to re-establish bile drainage, thus delaying the progression of fibrosis, with subsequent 
liver transplantation still required in many cases (3). 
 
The Kasai procedure was introduced in Japan in 1959 (3). The procedure aims to construct a new bile 
drainage system and if successful, increases survival and postpones liver transplantation. However, 
long term survivors are prone to develop complications, most commonly cholangitis, or liver cirrhosis 
leading to portal hypertension and oesophageal varices. Successful Kasai (re-establishment of bile 
flow) is much more likely if performed within the first 8 weeks of life, making early referral and prompt 
evaluation of suspected cases essential (4). A Canadian series found that patients receiving initial sub 
speciality care after 90 days of age had worse outcomes following Kasai operation (2). 
 
The prevalence of biliary atresia is estimated as 1 in 20 000 live births (3).  Since the global 
acceptance and utilisation of the Kasai procedure, many international studies have looked at the 
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outcomes and long term survival of post Kasai patients. Most of these studies have been conducted 
across Europe and North America, with very little research available in developing countries.  
 
A French national series reported the outcomes of Western countries to show short-term clearance of 
jaundice in 50-60% of cases, with 30-40% of patients reaching 10 years with their native livers and a 
third of patients reaching 20 years of age (1). 
 
A Canadian series conducted from January 1, 1985 to December 31, 2002 found 4- and 10-year 
survival rates of 77% and 75% respectively (2). The French national survey from 2003 to 2009 
reported a 5-year overall survival of 89% (1). The Japanese registry for 1989 to 1994 documented 
73.5% patient survival at 5 years (5). A study conducted across the United Kingdom and Ireland from 
1993 to 1995 revealed an overall survival rate of 85% at 5 years (6). 
 
Delayed presentation and late referral remain a major problem in the management of biliary atresia 
globally. Efforts aimed at promoting earlier referral through the creation of biliary atresia awareness at 
the primary health care level may play an important role in improving outcomes and survival post 
Kasai surgery. The United Kingdom has instituted a “yellow alert” educational programme aimed at 
expediting the referral of jaundiced infants. In Asia, a stool colour card is given to all mothers on 
discharge from postnatal services (2).  
 
A report of the experience in Southern Nigeria showed that late presentation and lack of resources 
pose major problems in the management of biliary atresia with only 62.5% of patients undergoing 
Kasai procedure with a mean age of death at 14.2 months (7). 
 
A previous study conducted in the surgical department at the Red Cross War Memorial Children’s 
Hospital (RCWMCH) reviewed 39 children undergoing Kasai procedure between January 1975 and 
January 1985 (8). The mean age of operation was 12.8 weeks. In the first 4 years of the study no 
patients established successful bile drainage. Thereafter 50% of Kasai procedures were successful in 
establishing bile drainage, however only 20% of these patients remained alive at the time of analysis. 
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These results are far below those seen in international studies. More recent statistics are not available 
at the RCWMCH. We are thus unable to compare our outcomes with current international experience. 
 
Biliary atresia places a significant burden on hepatobiliary services. A review of liver transplantation at 
The Wits Donald Gordon Medical Centre in Johannesburg, South Africa reported biliary atresia as the 
most common indication for liver transplantation in paediatrics (9) and it accounts of 57% of liver 
transplants performed at RCWMCH (10, 11). 
 
The purpose of this research is to review the current experience of biliary atresia at RCWMCH. Focus 
will be placed on the age of presentation, age at intervention, course of progress and outcomes of 
patients following Kasai operation. It is hoped that we will see a reduction in the mean age of surgery 
and improvement in the success of Kasai procedures since the earlier study. An awareness of the 
current management practices and outcomes within our referral system may identify areas of need in 
order to facilitate earlier referral and investigation of vulnerable patients. 
AIM 
To review the age of presentation to hospital, course and outcome of children presenting to or 
referred to Red Cross War Memorial Children’s Hospital with biliary atresia. 
OBJECTIVES 
1. To document the mean age of referral/presentation to RCWMCH in to order to ascertain 
whether patients accessing primary health care facilities or general practitioners are being 
referred to tertiary services timeously.  
2. To ascertain the mean age of Kasai (portoenterostomy) once within the RCWMCH system. 
3. To establish and document the outcomes following Kasai procedures at RCWMCH. 
4. To establish and document whether the age at Kasai procedure influences outcome of 
patients at RCWMCH. 






Outcomes will be assessed by looking at complications following Kasai and current survival rates. 
Complications looked at will include episodes of cholangitis, varices, ascites and bacterial 
peritonitis. Successful Kasai will be defined as complete clearance of jaundice with serum bilirubin 
< 20µmol/L within 3 months of Kasai procedure, as well as the presence of pigmented stools. 
Survival will be expressed as 2 year and 5 year survival rates, including overall survival, survival 
with native liver and survival post-transplant. 
METHODOLOGY 
1. STUDY DESIGN 
Retrospective folder review 
 
2. STUDY POPULATION 
Patients managed for biliary atresia at RCWMCH during the period 2003-2013. This is 
estimated to be approximately 75-100 cases. 
 
Inclusion Criteria: 
1. All patients in whom a diagnosis of biliary atresia has been made by clinical, biochemical 
and radiological grounds with surgical findings and liver histology consistent with biliary 
atresia 
2. Children with confirmed biliary atresia who did not undergo Kasai operation will be 
included in the study 
 
Exclusion Criteria: 
1. No records available 








Cases will be identified by a Clinicom search using the ICD 10 code for biliary atresia (Q44.2) 
within the defined study period. The Gastro-Intestinal Unit departmental database of liver 
biopsies and histology, as well as the RCWMCH transplantation register will be consulted. 
Medical records of identified patients will be retrieved for data collection. 
Data will be collected from patient files by the primary investigator only. A numerical identifier 
will be allocated to each case. Data collected will be captured on appropriate data collection 
sheets (Appendix 1), transcribed for digital storage and analysed using Microsoft excel. 
 
Data will include the following:  
Demographics: Date of birth, gender, race, age at first presentation to Red Cross, source of 
referral and number of visits to primary care before referral. 
 
Presenting features: reason for presentation, presence or absence of jaundice, stool colour, 
presence or absence of associated congenital abnormalities 
 
Diagnostic Studies: ultrasound, cholangiogram and biopsy 
 
Clinical and laboratory information: 
The following values will be collected at presentation, Kasai, 3 months post Kasai and 
annually thereafter. 
1. Growth Parameters: weight, height (expressed as Z scores) 
2. Laboratory values: Bilirubin (total and conjugated), AST/ALT, ALP/GGT, Albumin, FBC, 
INR. 
Age at Kasai procedure  
 
Complications post Kasai: Cholangitis, varices, ascites, growth failure and bacterial peritonitis 
 





This will largely take the form of a descriptive study. Data will be analysed by standard 
statistical methods using appropriate analytical software for statistical analysis. For 
descriptive statistics, continuous variables will be expressed as means ± SD (for normally 
distributed variables) or medians and interquartile ranges. Survival analysis will be by way of 
Kaplan-Meier curves. Where 2 groups are being compared using the log-rank test, a p-value 
of 0.05 will be regarded as significant. Statistical support will be obtained from the UCT 
School of Public Health prior to data analysis. 
 
5. DISSEMINATION PLAN 
Data will be presented at the SCAH Research Day, as well as at content relevant congresses. 
ETHICAL CONSIDERATIONS 
Potential risks and discomforts:  
No risk is anticipated with this study, as it is a retrospective study and no physical contact with the 
patient is required. No adverse effects are foreseen in any subject as a result of this study.  
 
Potential benefits: 
Potential benefits include improving the delivery and outcomes of Kasai procedure by identifying 
strategies for earlier referral and diagnosis of infants with biliary atresia. The study further offers the 




Confidentiality of individual patients will be assured since the data will only be analysed by the 
principal investigator. All patient data captured will be anonymised by assigning a numerical identifier. 
 
Informed Consent: 





Approval will be obtained from SCAH Ethics Committee at RCWMCH as well as the University of 
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3. LITERATURE REVIEW 
METHODS 
Objectives of literature review  
The objective of this study is to describe the current experience and outcomes of biliary atresia 
managed at Red Cross War Memorial Children’s Hospital (RCWMCH).  
The main objective of this literature review is to identify studies that would be useful in comparing our 
data to other cohorts, in both developed and developing countries.  
There is little information available in an African context, so recent work from other developing 
countries is valuable in assessing South African data.  
 
Literature Search Strategy  
An internet search, using the PubMed and Africa-Wide Information databases was undertaken. Terms 
used in the search were Biliary Atresia AND Kasai AND Outcome.  
The PubMed search revealed 178 articles with limits set as Humans, English, Full text, Child: birth-
18years. Titles and abstracts of articles were reviewed. 9 articles did not relate to biliary atresia and 
were immediately excluded. Articles were allocated to 3 groups of interest, namely, those describing 
international cohorts of biliary atresia with outcomes, long-term survivor experience and the effect of 
age at Kasai portoenterostomy. Surgical research pertaining to anatomical patterns, surgical 
techniques, re-do Kasai procedures, post-operative protocols and transplantation techniques were not 
reviewed. Research into laboratory indices as predictors of outcomes was also excluded. 40 relevant 
abstracts where identified, however 2 of these could not be retrieved in full text. A further 4 articles 
were identified from the references of these texts. 
 
A separate search was done for Biliary Atresia AND South Africa. This revealed 15 results, none of 
which discussed outcomes of Kasai. 3 of these papers were selected, which discussed the 
experience of liver transplantation services in South Africa. 1 article known to have been previously 
published from RCWMCH which was not identified via the PubMed search was retrieved individually. 
The Africa-Wide Information database revealed 9 articles. Duplicated articles from the previous 
searches were excluded. 3 original articles were identified and retrieved for analysis. 




Biliary atresia is a progressive obstructive cholangiopathy of unknown aetiology, occurring during the 
perinatal period. If left untreated it progresses to liver fibrosis and cirrhosis in the first few months of 
life, with death occurring within 2 years (1, 2). There is a wide variation in incidence across the globe, 
ranging from the highest incidence of 1 in 5000 live births occurring in Taiwan to 1 in 20 000 live births 
in Northern Europe (1, 3-8). Despite these variations it is the leading cause of end-stage liver disease 
in the paediatric population and remains the most common indication for liver transplantation in 
children (1, 9). The current surgical management of biliary atresia involves hepatic portoenterostomy 
(Kasai procedure) to re-establish bile drainage, thus delaying the progression of fibrosis, with 
subsequent liver transplantation still required in many cases (10). 
 
Biliary atresia can be described in 4 broad groups: Biliary atresia splenic malformation syndrome 
(BASM), Cystic biliary atresia (CBA), Cytomegalovirus-associated biliary atresia and isolated biliary 
atresia (4). BASM and CBA are considered “developmental biliary atresia” in which the onset of biliary 
occlusion is prenatal and evident by the time of birth. These carry a worse prognosis (4). Isolated 
biliary atresia accounts for 80-90% of cases (1) and may vary in time of presentation, level of 
obliteration of the biliary tree and degree of inflammation present (4).   
 
Biliary obstruction is classified into 3 anatomical types according to the Japanese Association of 
Paediatric Surgeons, based on the most proximal level of occlusion in the extrahepatic biliary tree (4, 
11). In type I obstruction is present at the level of the common bile duct, type II involves obstruction of 
the common hepatic duct and in type III there is obstruction of the entire biliary tree (11). Type III is 
the most common type (accounting for 90% of cases) and carries the worst outcome (4, 11, 12). 
 
The Kasai portoenterostomy (KP) was first described by Morio Kasai and was introduced in Japan in 
1959 (4, 10). However, it was only accepted in international practice in the 1970s (13). The procedure 
involves excision of the gallbladder and extrahepatic biliary tree to expose the porta hepatis. A loop of 
jejenum is then anastomosed to the cut surface to create a bilio-intestinal conduit (1, 4). 
 
12 
The procedure aims to construct a new bile drainage system and if successful, prolongs survival with 
native liver (SNL). Complete clearance of jaundice (defined at total bilirubin < 20µmol/L) post KP is 
achievable, with restoration of excretory and synthetic liver function (1, 4).  However, long term 
survivors are prone to develop complications, most commonly cholangitis and portal hypertension. 
Even those with successful drainage post Kasai will continue to develop fibrosis or cirrhosis. Ascites 
and variceal haemorrhage can complicate portal hypertension and will require prompt treatment. 
Long-term survivors with native liver are at an increased risk of malignancy including hepatoblastoma, 
hepatocellular carcinoma and cholangiocarcinoma (1). 
The Kasai procedure can be viewed as a palliative rather than a curative procedure, with the aim of 
delaying the development of cirrhosis and allowing time for growth prior to liver transplantation (1). 
Progression to chronic liver disease will still occur in 70% of patients in whom successful bile drainage 
is established, although the rate of progress varies. Time to transplant varies, but without 
establishment of biliary drainage is usually required within 6 months to 2 years (1, 4). Many studies 
have focused on trying to predict success of Kasai surgery and factors contributing to long-term 
survival with native liver.   
Age at Kasai surgery 
Emphasis is placed on early recognition, referral and intervention to optimise outcome. Liver fibrosis 
is a time-dependent process and it is thus only logical that the age at which Kasai is performed should 
affect its success rate (14). An age cut off of 60 days was previously suggested as a critical time, 
beyond which the success of Kasai rapidly declines (15), with primary liver transplantation 
recommended in patients presenting beyond this point (1, 16). Subsequent studies have failed to 
substantiate this notion and do not recommend a strict cut off in terms of offering Kasai. Unfortunately 
many patients still present beyond 60 days of life, with the best management in this scenario 
remaining controversial.   
Davenport et al (2004) reported on 35 patients who underwent Kasai beyond 100 days of life (17). 
The 5-year and 10-year survival with native liver rates (SNL) were 45% and 40% respectively. He 
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suggests that no clinical test can be used to predict the success of Kasai without actually preforming 
the procedure.  
 
Scheon et al (2001) in the United States concluded that there was no contraindication to performing 
Kasai beyond 75 days of life (16). This report looked at 31 children undergoing Kasai at the Children’s 
Healthcare Centre of Atlanta. Those in whom Kasai was performed at or before 75 days had 52% rate 
of clearance (defined as bilirubin < 2mg/dL), whereas those undergoing Kasai beyond 75 days had a 
83% success rate. This study only describes patients who underwent KP and does not offer any 
information on patients who may not have been offered KP. KP was only performed in 6 patients 
beyond 75 days of age, it is not known whether other patients beyond 75 days who may have 
presented with more advanced portal hypertension and cirrhosis were declined KP. The selection of 
patients with less severe clinical disease and complications may have contributed to the high success 
rate seen in this age group. Notably 4 patients underwent Kasai between 90 and 120 days, all of 
these were successful in clearing jaundice. 
 
Wong et al (2010) reviewed 103 patients between 1980 and 2008 (15). Successful outcome was 
defined as clearance of jaundice (<20µmol/L) without the need for transplantation in the first year after 
surgery. Patients were stratified into 4 groups: Kasai performed < 60 days (success 53.7%), 61-
80days (success 81.5%), 81-100 days (success 55.6%) and > 100 days (no successful cases). This 
study considered 100 days to be the point at which irreversible liver damage had already occurred. 
 
Chen et al (2012) reviewed 452 infants with Type III biliary atresia and stratified age of Kasai in 3 age 
categories: < 60 days (success 39.7%), 60-90 days (success 41.8%) and > 90 days (success 36.1%) 
(18). (Success was defined as bilirubin < 20µmol/L.) 
 
Nio et al (2010) reviewed 242 with Type III biliary atresia undergoing Kasai, at an average age of 79.7 
days (19). Patients were allocated to 6 groups progressing in 30 day intervals, from group 1 being 
those who underwent Kasai less than 31 days and group 6 those in whom Kasai was performed 
beyond 150 days of life. None of the 8 procedures performed beyond 150 days were successful 
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(bilirubin < 2mg/dL). This study found that age at Kasai had a significant impact on clearance of 
jaundice, but not on SNL provided Kasai was done before 4 months of age (19). 
 
The above research concluded that age is not the sole factor in determining prognosis and that Kasai 
surgery should not be denied on age criteria alone.  
 
In contrast Serinet et al (2009), Tiao et al (2007) and Zhen et al (2015) considered age of Kasai to be 
an important determinant of success.1 
 
Serinet et al assessed the impact of age at Kasai operation on its results in late childhood and 
adolescence (20). The study reported the best results if Kasai was performed before 30 days of life, 
however late Kasai operations (beyond 90 days) still carried a 15-year SNL of 13.4%.  
 
Taio et al described 93 patients undergoing Kasai in a single-centre in Taiwan from 1986-2005 and 
compared those performed before and after 60 days of life (21). They found a significant difference in 
the jaundice-free survival rates (48% vs. 27%). 
 
Zhen et al looked at designing an early scoring system to predict the early outcomes of Type III biliary 
atresia after Kasai operation (11). They showed the rate of early cholangitis, age at Kasai, time to 
clear jaundice, post-operative bilirubin and transaminases and surgical method used differed 
significantly between the survivor and non-survivor group at 2 years post Kasai. Early cholangitis was 
reported as the most powerful independent factor for prognosis. Tiao’s study reported no significant 
difference in 3 and 5-year SNL between patients with and without cholangitis (21). 
 
These figures suggest that an arbitrary age cut off should not be applied when offering Kasai 
procedure. There is still a significant chance of delaying liver transplantation even when performing 
Kasai beyond 100 days of life. Liver transplantation is more successful if performed later in life (16). 
Infant donor livers are in short supply and tend to have worse function than livers from older donors. 
Transplantation is technically more difficult in small children and carries higher complication rates. It is 
                                                          
1 References provided below 
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therefore preferable to delay transplantation for as long as possible to allow for growth and 
development prior to transplantation, in order to achieve better success. 
Nonetheless, the aim should still be towards prompt diagnosis and management of biliary atresia. The 
Canadian series (2007) found that patients receiving initial sub speciality care after 90 days of age 
had worse outcomes following Kasai operation (9). Data from the French National Series (2013) (2) 
and the Swiss National Study (2008) (6) both showed a strong correlation between age at Kasai and 
SNL. 
Centralization of surgical care 
Research in the United Kingdom showed that the outcome of children with biliary atresia is related to 
the caseload of the surgical centre performing KP, with centres performing more than 5 Kasai 
operations per year yielding better SNL and overall survival rates (7). In response, in 1999 3 
designated centres were established where both Kasai operation and liver transplantation can be 
performed.  
Davenport et al has subsequently reviewed the outcome of these policy changes, publishing their 
findings in 2004 and 2011 (14, 22). Both papers reported a median age at Kasai of 54 days with initial 
clearance rates (defined as bilirubin < 20µmol/L within 6 months of surgery) above 50%. In 2004 the 
4-year SNL was estimated as 51%, with an overall survival of 89%. The 2011 article reports 5- and
10-year SNL as 46% and 40% respectively, with overall survival rates of 90% and 89%. These
outcomes are a significant improvement on figures from the UK and Ireland reported for 1993-1994, 
with 5- and 10-year SNL of 30% and 44% respectively (7, 23).  
The promising results of centralization of services were not reflected in Scotland, as reported by 
Tayler et al in 2013 (5). As none of the designated centres are located in Scotland, they attributed this 
to lengthy workups delaying referral for definitive management.  
Serinet et al (2006) compares the decentralized policy of care in France with the centralized services 
in the United Kingdom (24). Overall 4-year survival between France and UK were comparable at 
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87.1% and 89% respectively. However, 4-year SNL was lower in the French data (42.7% compared to 
57%). This was attributed to suboptimal results in the French centres performing 2 or less Kasai 
operations per year. 
 
Schreiber et al (2010) reviewed the effect of centre caseload in Canada and reported no effect on 
biliary atresia outcomes between centres (25). However, this study only reported a 4-year SNL of 
39%, which is significantly lower than the UK figures. 
 
Anatomical malformations 
Davenport et al (2008) compared the aetiology of biliary atresia and outcomes of KP in 225 cases 
(26). Patients were divided into 3 aetiological groups: isolated biliary atresia, BASM and CBA. The 
developmental biliary atresia’s presented earlier at a median age 47 days, versus a median age a 58 
days in the isolated biliary atresia group. Overall 56% achieved successful drainage post-Kasai with a 
65% 2-year SNL. Infants with isolated biliary atresia showed no statistical difference in jaundice 
clearance or in SNL across the age cohorts. However, there was a marked detrimental effect of age 
at Kasai in the BASM and CBA groups.  
 
In terms of isolated biliary atresia types I and II, carry a better prognosis than Type III (4). 
 
International Cohorts/Outcomes 
The success rates of Kasai operation, as well as long-term survival in biliary atresia vary within 
different centres worldwide, with many international studies looking at these outcomes. 
 
A French national series reported the outcomes of Western countries to show short-term clearance of 
jaundice in 50-60% of cases, with 30-40% of patients reaching 10 years with their native livers and a 
third of patients reaching 20 years of age (2). 
 
A Canadian series conducted from January 1, 1985 to December 31, 2002 found 4- and 10-year 
survival rates of 77% and 75% respectively (9). The French national survey from 2003 to 2009 
reported a 5-year overall survival of 89% (2). The Japanese registry for 1989 to 1999 documented 
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75.3% patient survival at 5 years (27). A study conducted across the United Kingdom and Ireland 
from 1993 to 1995 revealed an overall survival rate of 85% at 5 years (7). A multi-centre study in the 
United States from 1997 to 2000 reported 56% SNL at 2 years, although this study had a shorter 
period of follow up than those conducted in other countries (28). 
 
The following table summarises the age of Kasai surgery, jaundice clearance rates and survival 
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a Reported as days in median/mean 
b Defined as achieving a level of less than 20µmol/L (or 1.5mg/dL) 
c Defined as achieving a level less than 2mg/dL 
 
Long-term outcomes 
Various authors have looked at the long-term outcomes of biliary atresia survivors. Bijl et al (2013) 
performed a systematic review of patients living beyond 20 years with their native livers (10). This 
review found 184 patients alive above the age of 20 years, 88% of these patients still had their native 
liver. Of those 60.5% suffered from liver related complications: 100% had experienced episodes of 
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cholangitis, 80% had portal hypertension with 45% of these having experienced an episode of 
gastrointestinal bleeding. 
 
Another systematic review conducted by Jimenez-Rivera et al (2012) found that 10-year overall 
survival ranged from 66.75 to 89% (30). 
 
Nio et al (1997) reviewed the outcomes of long-term survivors in Japan (31). Of 85 patients alive more 
than 10 years on from Kasai, 72 (84%) remained jaundice free.  
 
Shinkai et al (2009) reviewed 80 patients undergoing Kasai at a single-centre in Japan (32). Survival 
rates with native liver were 63%, 54% and 44% at 5-, 10- and 20-years respectively. Of the 35 
patients alive with native liver beyond 20 years, 71% had normal bilirubin levels, although 47% had 
already been diagnosed with cirrhosis and portal hypertension. This is not surprising as those with 
successful KP and clearance of bilirubin are more likely to survive. Two patients in this review died of 
liver failure and 5 underwent transplantation in their twenties. 
 
Hadzic et al (2002) and McKiernan et al (2007) have reported on long-term experience in the UK. 
Hadzic reviewed 244 patient records and found 11% of patients with no features of chronic liver 
disease 10 years post Kasai (33). Despite normal liver function and good quality of life, 40% of these 
patients still had biopsy evidence of cirrhosis. The outcome in these patients was not influenced by 
isolated episodes of cholangitis.  
 
McKiernan followed 91 patients receiving Kasai between 1993 and 1995 for 13 years (23). Of the 50 
successful KP’s, 80% of these patients were still alive with native liver, with a 13-year actuarial 
survival rate of 82.5%. KP was unsuccessful in 41 of the original patients. All of these had either died 
or received a liver transplant at the time of follow up. 13-year SNL was 43.8% and overall survival 
83.8% for the entire group.  
 
20 year SNL is possible, but the majority of these patients have complications of chronic liver disease, 




Experience in developing countries 
Despite a wealth of information from developed countries, very little information is available in Africa 
and other developing nations. 
 
Mshelbwala et al (2007) described the challenged in Nigeria (34). They reported 14 cases of biliary 
atresia, with a median age at presentation of 16 weeks. 7 of these patients had presented to primary 
health care services with neonatal jaundice, but were not referred for further investigation. 11 of the 
patients already had cirrhosis and coagulopathy at the time of presentation, the remaining 3 patients 
were fit for Kasai operation. 1 of these patients was well post Kasai, but died of gastroenteritis at 2 
years; 1 died from cholangitis 8 weeks post Kasai and 1 did not recover from anaesthesia at the time 
of Kasai. 
 
A subsequent report of the experience in Southern Nigeria by Okoro et al (2013), showed that late 
presentation and lack of resources still pose major problems in the management of biliary atresia, with 
only 62.5% of patients undergoing Kasai procedure and a mean age of death at 14.2 months (35). 
Liver transplants are not performed in Nigeria, which contributes to the poor overall survival.  
 
Aydogdu et al (2004) reviewed 27 patients with biliary atresia in Turkey, the median age at diagnosis 
was 63.5 days with median age at Kasai 67.5 days (36). Only 2 out of 25 Kasai operations performed 
were successful (bilirubin < 20µmol/L). Kasai operations were carried out at various hospitals and only 
referred to specialist liver unit post-operatively; this is likely to contribute to the low success rate.  
Overall 5 year survival was 10%, far lower than in other European cohorts.  
 
Lee et al (2009) described the outcomes of 57 patients with biliary atresia at a single-centre in 
Malaysia (37). The median age at presentation was 62 days. 48 patients underwent Kasai at a 
median age of 70 days, with a success rate of 44% (bilirubin < 20µnol/L within 6 months). 2-year SNL 
and overall survival were 37% and 40% respectively. Liver transplantation is not available in the 




Reasons for late diagnosis in all of these reports were attributed to lack of parental insight and poor 
health seeking behaviours, geographical and financial accessibility of health care, repeated 
reassurance by medical staff without appropriate referral or investigation of neonatal jaundice and 




South African Experience: 
A previous study conducted in the surgical department at the Red Cross War Memorial Children’s 
Hospital (RCWMCH) reviewed 39 children undergoing Kasai procedure between January 1975 and 
January 1985 (12). The mean age of operation was 12.8 weeks. In the first 4 years of the study no 
patients established successful bile drainage. Thereafter 50% of Kasai procedures were successful in 
establishing drainage, however only 20% of these patients remained alive at the time of analysis.  
 
These results are far below those seen in international studies. More recent statistics are not available 
at the RCWMCH. We are thus currently unable to compare our outcomes with those of international 
cohorts. 
 
Biliary atresia places a significant burden on hepatobiliary services. A review of liver transplantation at 
The Wits Donald Gordon Medical Centre in Johannesburg, South Africa reported biliary atresia as the 
most common indication for liver transplantation in paediatrics and it accounts of 57% of liver 
transplants performed at RCWMCH (38-40). 
 
The Role of Screening: 
Delayed presentation and late referral remain a major problem in the management of biliary atresia 
globally. Efforts aimed at promoting earlier referral through the creation of biliary atresia awareness at 
the primary health care level may play an important role in improving outcomes and survival post 
Kasai surgery. The United Kingdom has instituted a “yellow alert” educational programme aimed at 
expediting the referral of jaundiced infants. In Asia, a stool colour card is given to all mothers on 
discharge from postnatal services (9, 29, 41).  
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The stool colour card was established in Taiwan in 2004 and comprises 6 photographs of infant stool. 
3 colours of stool are labelled as abnormal, namely clay coloured, pale yellow and light yellow. 
Contact details are available on the card for a stool card registry centre which responds to all reports 
within 24 hours with advice and appointment date if indicated. 
Since the introduction of this screening method biliary atresia has been diagnosed earlier with the 
percentage of patients undergoing Kasai before 60 days improving from 49.4% to 65.7%. Jaundice 
clearance post Kasai has improved from 34.8% to 60.8%, with 5-year jaundice free SNL improving 
from 27.3% to 64.3% (41). 
What this research will offer: 
Davenport suggests that a jaundice clearance rate of 50% should be the benchmark for institutions 
offering Kasai, with survival rates of 90% attainable in countries with access to liver transplantation 
(4). 
We are currently unable to measure our experience at RCWMCH against the international standards 
described above. The purpose of this research is to review the current experience of biliary atresia at 
RCWMCH. It is hoped that we will see a reduction in the mean age of surgery and improvement in the 
success of Kasai procedures since the earlier RCWMCH study. An awareness of the current 
management practices and outcomes within our referral system may identify areas of need in order to 
facilitate earlier referral and investigation of vulnerable patients.  
Focus will be placed on 3 important aspects which will assess the efficacy of different stages in our 
management pathway. 
The median age at Kasai reflects effectiveness of primary health care services in identifying and 
referring suspected cases of biliary atresia. The diagnostic process in secondary and tertiary institutes 
also plays a role in improving the age at which Kasai is performed. 
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The percentage of jaundice clearance is a reflection of surgical expertise within the centre. Long-term 
survival with native liver reflects both surgical practice, as well as the level of on-going medical care 
post Kasai. Accessibility of services, which is known to be a problem in our context, will also impact 
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Background 
Biliary atresia (BA) is the leading cause of end-stage liver disease in the paediatric population and 
remains the most common indication for paediatric liver transplantation in South Africa.  
Objectives 
This study aimed to describe the age of presentation, clinical course and outcome of infants presenting 
to Red Cross War Memorial Children’s Hospital (RCWMCH) with BA.  
Methods 
A retrospective folder review was conducted on all patients with BA presenting to RCWMCH between 
January 2003 and December 2013. The main outcomes assessed were median time to presentation to 
tertiary services, clearance of jaundice post Kasai procedure (bilirubin <20µmol/L) and 2- and 5-year 
overall survival (OS) and survival with native liver (SNL). 
Results 
The median age at presentation in the 80 cases reviewed was 70 days. Kasai procedure (KP) was 
performed in 62 (77.5%) patients at a median age of 68 days. 18 patients who presented late did not 
undergo KP. Clearance of jaundice was achieved in 39% of KPs. 13 patients underwent KP beyond 90 
days with a success rate of 38%. 2- and 5-year SNL rates were 41% and 37.5% respectively with OS 
of 59% at 2-years and 56% at 5-years. Liver transplant was only performed in 12 of the 54 patients 
who showed progression to require transplantation. 
Conclusions 
Jaundice clearance post KP and SNL compared favourably with international figures, however, lower 
overall survival rates reflected lack of access to transplantation. Age at KP was not a predictor of poor 
outcome. 
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What is known What is New 
 Short-term clearance of jaundice has been
achieved in 50-60% of cases in developed
countries.
 Emphasis has been placed on early
recognition, referral and intervention to
optimise outcome.
 Previously 60 days was recommended as a
cut off for performing KP, currently much
debate exists around the benefits of
performing late KP.
 Little information is available in the
developing world.
 This provides valuable insight into what is
achievable in a resource limited setting.
 A significant proportion (38%) of patients
benefited from KP performed beyond 90
days.
INTRODUCTION 
Biliary atresia (BA) is a progressive obstructive cholangiopathy of unknown aetiology, occurring during 
the perinatal period. If left untreated it rapidly progresses to hepatic fibrosis and cirrhosis, with death 
occurring within 2 years (1, 2). It is the leading cause of end-stage liver disease in the paediatric 
population and remains the most common indication for liver transplantation in children (1, 3). The 
current surgical management of biliary atresia involves Kasai portoenterostomy (KP) to re-establish 
bile drainage, thus delaying the progression of fibrosis, with subsequent liver transplantation (LT) still 
required in many cases (1, 3-5). 
Although KP can improve long-term survival, progression to chronic liver disease will still occur in 
70% of patients in whom successful bile drainage is established (6). The rate of progression and time 
to transplant varies.  
Factors thought to predict success of KP and long-term survival with native liver (SNL) include age at 
surgery (2, 7, 8), aetiology and anatomical pattern of BA (1, 9), experience of the surgical centre (1, 
10) and the degree of liver fibrosis present at the time of KP (9, 11). Data from French (2), Swiss (7)
and Canadian (8) cohorts showed a strong correlation between age at Kasai and SNL. Emphasis is 
therefore placed on early recognition, referral and intervention to optimise outcome. Recently 
researchers have challenged the concept of an age cut off beyond which Kasai should no longer be 
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offered. Davenport et al reported a 5-year SNL of 40% in patients undergoing Kasai beyond 100 days 
(12). 
Outcomes vary world-wide, with short-term clearance of jaundice achievable in 50-60% of cases (10, 
13-16), and a 10-year SNL of 30-40% (10, 13, 17, 18) reported in literature from Western countries. 
Despite a wealth of information from developed countries, very little information is available in Africa 
and other developing nations. The purpose of this research is to review the current experience of 
biliary atresia at Red Cross War Memorial Children’s Hospital (RCWMCH) in South Africa with 
emphasis on age at presentation, age at KP and outcomes in patients following KP at our institution. 
METHODS  
This is a retrospective descriptive study conducted within the Department of Paediatrics, RCWMCH, 
Cape Town, South Africa. Patients managed within the department from January 2003 to December 
2013 were included. The study was approved by the University of Cape Town Faculty of Health 
Sciences Ethics Committee (HREC REF: 137/2014). 
Inclusion Criteria: 
Patients in whom a diagnosis of BA was made on clinical, biochemical and radiological grounds with 
surgical findings and liver histology consistent with BA, including those who did not undergo KP were 
analysed. Only patients managed primarily at RCWMCH during the study period were included. 
Patients referred for transplant assessment after initial management at other tertiary institutions did 
not form part of this study. 
Analysis of Records: 
Cases were identified through the RCWMCH clinical data base using the International Statistical 
Classification of Diseases Code (ICD-10) allocated to BA. Records of attendance for the liver and 
transplant clinics, as well as current and old transplant waiting lists were reviewed to ensure no cases 
were missed. A review of all files was conducted from May to July 2014, by the primary author.  
Data collected from patient charts included unique patient code, date of birth, sex, referral site, age of 
jaundice onset (in weeks), date of presentation, presence of congenital anomalies, presence of 
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jaundice and stool pigment, imaging results (ultrasound, hepatobiliary scintigraphy, intraoperative 
cholangiogram), whether KP was performed, date of KP, liver histology, success of KP, complications 
(ascites, cholangitis, varices, fractures), tuberculosis, progression to require transplantation, suitability 
for transplant listing, whether liver transplant (LT) was performed, date of LT, date of last visit and 
final outcome including cause of death. Laboratory indices (full liver function tests, albumin, 
haemoglobin and international normalised ratio) were recorded at time of presentation, time of KP, 3 
months post KP and annually thereafter. 
Liver biopsies were scored using Lee’s 15 point histological scoring system for neonatal cholestasis 
(19), by a single paediatric histopathologist. Cirrhosis was classified as present if there was porto-
portal bridging involving more than 50% of the portal tracts.  
Outcome measures: 
The latest outcome status was documented as alive, dead, lost to follow up or transferred to another 
institution. Successful KP was defined as clearance of jaundice with serum bilirubin < 20µmol/L within 
3 months of surgery. Survival was expressed as 2- and 5-year survival rates, including overall survival 
(OS) and survival with native liver. OS was defined as beginning at birth and ending at death or last 
follow-up; SNL starting at birth and ending at death (based on how many patients could have reach 2 
or 5 years of age by 31 July 2014). 
Statistical Analysis: 
All analyses were done using Stata Statistical Software Release 13 (StataCorp LP, College Stat). 
Ages are quoted as median and interquartile range (IQR). Fisher’s exact tests were used to compare 
categorical data. The distribution of numerical data was assessed and the Student t-test or Mann-
Whitney U test applied as appropriate. A P-value of 0.05 was regarded as significant. Survival rates 
were estimated using the Kaplan-Meier method. 
Full data was not available in all medical records, for these variables number (n) was declared. For 
patients lost to follow up (LTFU) the date of their last visit was utilised when calculating survival. 
Cases LTFU immediately post-KP were not included when calculating success of KP.  
Limitations: Anatomical classification of BA was not recorded. Data was limited by that available in 




152 cases were identified, 6 files were not traceable and 3 were excluded due to insufficient clinical 
records. Of the remaining cases, 80 were managed primarily by RCWMCH (30 male, 50 female). 
Sixty-three patients were referred to RCWMCH at the time of transplant assessment, after initial 
management at other centres and were therefore not included in the cohort.  
16 (20%) had associated congenital anomalies. 4 of these involved biliary atresia splenic 
malformation (BASM) syndrome (2 with significant cardiac lesions: 1 with septal defects and an 
interrupted inferior vena cava, 1 with transposition of the great vessels and asplenia). Situs inversus 
was not present in any of the BASM cases. The remaining anomalies included: 4 patients with 
haemodynamically insignificant cardiac lesions; 3 with major congenital cardiac lesions; 3 choledochal 
cysts; 1 case of renal tract pathology and 1 chromosomal disorder (47XXX) with cardiac lesions. 
Age at presentation and surgery: 
Jaundice was noted during the first week of life in 81% of cases (57/70). The median age at 
presentation was 70 days, IQR 44-105.5. Sixty two patients underwent KP at a median age of 68 
days, IQR 54-86. The median age at presentation of the Kasai group was 61 days, IQR 42-79. 
Median interval between initial presentation and KP was 8 days, IQR 5-13. Demographic data as well 
as initial findings and investigations are summarised in Table 1. 
Patients with no Kasai Procedure: (n = 18, see outcome summary in Figure 1) 
18 (22.5%) patients who were referred late did not undergo KP (median age at presentation 166.5 
days, IQR 142-208). None of these patients were alive with their native livers at the time of data 
collection. 3 patients were LTFU, 7 died without liver transplantation and 8 patients received 
cadaveric liver grafts, 2 of whom have died. 1 patient died 1 month post-transplant from overwhelming 
sepsis, the second patient died 6 months post-transplant secondary to hepatic vein thrombosis with 
fulminant liver failure. The median age of death in this group was 15.1 months, IQR 13.4-17.8. 
Patients undergoing Kasai Procedure: (n = 62, see outcome summary in Figure 1) 
KP was performed in 62 (77.5%) of patients with outcomes depicted in Figure 1. Three patients 
defaulted immediately post KP and were excluded from further analysis of KP success.  
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Thirty six (61%) of the 59 patients with known outcomes were ultimately unsuccessful (median age at 
operation 76.5 days, IQR 55.5-86.5). Three patients died of complications related to the KP (2 
breakdown of anastomosis progressing to sepsis, bowel/liver necrosis and multi-organ failure (MOF) 
and 1 bowel obstruction with sepsis and MOF). Of the remaining 33 patients with persistent jaundice 
post KP only 9 were alive with native liver at data collection, 10 patients had been LTFU, 3 underwent 
LT (1 of whom suffered from chronic rejection and died 4 years post LT), 11 died without LT.  
Sixteen of the 59 patients (27.1%) established successful drainage 3 months post KP, however a 
further 7 (11.9%) patients established clearance beyond this point (6 by 6 months, age of clearance 
was not documented in 1 case). Including the cases which cleared beyond 3 months increases the 
overall success rate to 39% (23/59). The median age at surgery of successful KP was 57 days, IQR 
51-88. Twenty of these patients were still alive with their native liver, 19 of whom remained jaundice
free. 1 patient underwent successful LT at the age of 2 years 6 months. Follow up data was not 
available on 2 patients. 
Age at Kasai 
Of the 59 patients where outcome of KP was known, 25 patients (42.4%) underwent KP before 60 
days of life with a success rate of 28%. Twenty-one patients (35.6%) were operated between 61 and 
90 days with a success rate of 19%. An additional 13 patients (22%) underwent KP beyond 90 days 
with a success rate of 38%. The differences in success rates across these age categories was not 
statistically significant (P = 0.9). The oldest age at KP was 148 days. This procedure was successful 
in establishing bile drainage and the patient remained jaundice free 4 years post KP. 
Cirrhosis was evident in 58.8% of patients at the time of Kasai (30/51). The median age at Kasai in 
those with no evidence of cirrhosis was 56 days compared to a median of 82 days in those where 
cirrhosis was present (P = 0.001). There was no statistical significance between the presence of 
cirrhosis and success of KP (P = 0.576). Of those with evidence of cirrhosis on histology 26% (7/27) 
still had successful outcomes of KP. 
Liver Transplantation: 
Of 73 patients for whom follow up data was available 54 (74%) progressed to require transplantation. 
Only 20 of the 54 (37%) were placed on the transplant list (16 active, 4 inactive listing), with the 
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remaining 34 (63%) being excluded from potential transplantation. Unfavourable social circumstances 
such as poor compliance with medical treatment and follow up, inadequate sanitation, parental 
substance abuse and distance from the transplant centre formed the main grounds for exclusion 
(n=16, 47% of those excluded from LT; 30% of the 54 patients requiring LT). Two patients were 
medically unfit to undergo LT (1 due to active tuberculosis). One patient was not from South Africa, 8 
defaulted prior to completion of the transplant assessment and 4 died before they could be listed 
A total of 12 patients underwent LT (15% of the total cohort, 22.2% of those requiring LT) at a median 
age of 31.5 months, IQR 18.9-34.2. The outcomes of these patients were described above. (Figure 1) 
Clinical course and complications: 
Of the 29 patients who were alive with their native liver at the end of data collection, only 3 (10.3%) 
were alive without complications. Cholangitis was the commonest complication occurring in 21 of 
these patients (72.4%), of these 13 patients suffered recurrent episodes of cholangitis. Ascites 
occurred in 6 of the 29 patients (20.7%). Routine endoscopy was not performed and thus varices 
were only diagnosed after an episode of melaena or hematemesis. Five of the 29 patients (17.2%) 
experienced variceal bleeds. One patient suffered 2 consecutive femur fractures. Pulmonary 
tuberculosis occurred in 6 patients (20.7%).  
The frequency of complications for the full cohort is expressed in Table 2. 
Sixty two patients underwent KP and information regarding cholangitis was not available for 2 of these 
patients. Of the remaining 60 patients, 44 experienced episodes of cholangitis (73.3%). Fifteen of these 
patients were lost to follow up and hence outcome data was only available for 45 patients. Of the patients 
that died during the study period, 84.6% had experienced at least 1 episode of cholangitis (11/13). 
Cholangitis was also seen in 71.9% of patients who ultimately survived (23/32). There was no statistical 
significance in the occurrence of cholangitis and the outcome of survival (P=0.467). 
Reliable growth parameters were not available in many records and growth failure was thus unable to 





Outcome and Survival at 2 and 5 years: 
Figure 1 highlights the outcomes of the 80 patients managed in this cohort. The overall 2-and 5 year 
survival rates were 58.8% (30/51) and 56.3% (18/32) respectively. Native liver survival was 41.2% 
(21/51) and 37.5% (12/32) at 2 and 5 years respectively. See Figure 2 for Kaplan Meier survival 
curves. 
DISCUSSION 
The RCWMCH is currently the only dedicated tertiary paediatric hospital in South Africa. The hospital 
receives referrals from all 9 provinces within the country as well as from across African borders. Many 
of these patients come from poor socioeconomic backgrounds with limited access to primary health 
care and follow a prolonged route to tertiary referral.  
All KPs performed at RCWMCH follow a standard post-operative protocol including steroids and 
antibiotic prophylaxis, with vitamin K and ursodeoxycholic acid commenced from day 5 post 
procedure. As this is the standard of care for all patients, the benefits were not assessed in this study. 
(Appendix attached for shared surgical/medical care package) 
Liver transplantation remains a scarce resource. Transplants have been performed at RCWMCH 
since 1991 (20). In 2005 the Donald Gordon Medical Centre (DGMC), a privately-owned medical 
facility began its own transplant programme (20, 21). Currently the RCWMCH is only able to offer 
cadaveric LT, with the shortage of donor livers contributing to long waiting lists. Socio-economic 
factors play a pivotal role in the evaluation of transplant candidates. Many patients live in rural areas 
situated far from the transplant centre with limited access to medical facilities, especially specialised 
services; immunosuppressive therapy and intensive monitoring that would be required post 
transplantation. These families often live in extreme poverty with no electricity, inadequate sanitation, 
as well as high rates of malnutrition and infectious diseases (22). In this series 30% of patients 
requiring LT were excluded from the transplant list due to the above mentioned socioeconomic factors 
preventing safe transplant. 
Late presentation to tertiary services remains a major problem in South Africa. The median age at 
presentation was 70 days in this study, much later than that reported in International Cohorts. 
McKiernan reported a median age at referral to surgical centre of 40 days in the United Kingdom and 
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Ireland (17).  The United States (16) and Canada (8) have reported 53 and 55 days at referral to 
tertiary centres respectively. Our figures are closer to those reported in other developing countries, 
namely Malaysia (62 days) (23) and Turkey (63.5 days) (24). Reasons for late presentation in our 
setting included poor parental knowledge resulting in delayed health seeking behaviours, distance 
from health care facilities and financial constraints limiting access to medical services, high work-
loads and lack of awareness regarding causes of prolonged neonatal jaundice amongst primary 
health care staff resulting in inappropriate advice being given to parents and delayed referral. 
Recent research has challenged the concept of a critical time point of 60 days beyond which patients 
should be offered primary liver transplantation instead of KP. This series showed a median age at KP 
of 68 days, with an overall success rate of 39%. There was no statistical significance comparing age 
at KP with success of the procedure. When stratified by age the highest success rate (38%) was 
achieved in the group who underwent KP beyond 90 days. This figure is comparable to that reported 
by Chen et al which showed 39% clearance when performed beyond 90 days (25). Similar results 
were published by Schoen et al in the United States who showed 83% beyond 75 days (26) and by 
Wong et al in Hong Kong who reported 55.6% success between 81 and 100 days (11). Davenport et 
al reported 5- and 10-year survival rates of 45% and 40% respectively in patients undergoing KP 
beyond 100 days (12). 
Figure 2b depicts the Kaplan Meier survival curves stratified by age at KP. In this graph the 61-90 day 
subgroup appears to have worse outcomes than those who underwent KP beyond 90 days. It should 
be considered that the Kaplan Meier method provides a crude estimation of survival without adjusting 
for any confounding factors. Cox-regression analysis was not possible due to the small subgroup 
sizes. This difference did not appear to be due to the degree of fibrosis present at the time of KP or 
the presence of other congenital anomalies. The apparent better performance of the > 90 days group 
could possibly be explained by sample bias as KP was not offered to all patients beyond 90 days. 
Those with clinical cirrhosis and portal hypertension did not undergo KP. These patients would have 
had a poor outcome if shown in this graph.  
These figures suggest that an arbitrary age cut off should not be applied when offering Kasai 
procedure. There is still a significant chance of delaying liver transplantation even when performing 
Kasai beyond 100 days of life (12). KP should be considered on an individual basis in cases of late 
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presentation taking into account the clinical severity of disease, presence of established cirrhosis and 
portal hypertension. In the South African context where access to LT is limited, life expectancy and 
quality of life can be improved by offering KP even in those presenting beyond 90 days. In patients 
who fulfil the social criteria for transplantation, delaying LT benefits patients by allowing time for 
growth and immunisations prior to transplantation.  
 
Definitions of successful KP vary amongst authors. Bilirubin values of <20µmol/L are the most 
commonly quoted (2, 9, 11, 18, 25, 27), but <2mg/dL (34µmol/L) has also been used (26, 28). Grizelj 
et al used a cut off of 3 months post KP to define successful clearance of jaundice (27), although 
other authors have been more liberal in their cut off with Davenport (9), Lee (23) and Hung (29) using 
6 months and McKiernan (18) and Tiao (28) accepting the target bilirubin levels at any time post KP. 
When applying a cut off of 3 months in this study successful clearance of jaundice was only achieved 
in 27% of cases. However, if this is expanded to include the 7 cases which cleared beyond 3 months, 
the success rate increased to 39% which is comparable with jaundice clearance rates achieved in 
France (40%) (15), Netherlands (38%) (30) and US (40%) (16). This is still below those achieved in 
Japan (62%) (13), Taiwan (59%) (14) and the UK (55%) (10). 
 
Cirrhosis was evident in almost 60% of patients undergoing KP. Although the presence of cirrhosis 
did not have a statistical impact on the success of procedure, cirrhosis was associated with increasing 
age at KP. Davenport et al reported that histological degree of fibrosis had no value in predicting 
success and furthermore that the presence of cirrhosis at the time of KP had no significant survival 
disadvantage, in a series reviewing the outcomes of KP beyond 100 days (12). 
 
This cohort showed a high rate of cholangitis and complications of portal hypertension including 
ascites and variceal bleeding. Cholangitis was common, occurring in 73% of those who underwent KP 
(Table 2). This is comparable to figures seen in other literature (28, 29). Zhen et al (31) reported early 
cholangitis to be the single most powerful predictor for prognosis, although other authors have found 
no association between cholangitis and survival (16, 28). In this study cholangitis was not associated 
with a worse survival outcome, although the limited numbers need to be taken into account when 
interpreting the statistical significance of this data. It is essential that cholangitis is treated promptly 
37 
 
and aggressively to preserve liver function. 20% of patients in this cohort were lost from follow up. 
Parents should be counselled about the potential for complications and the development of chronic 
liver disease post KP, as life-long follow up is essential in order to delay progression of liver disease 
and begin appropriate transplant assessment when required. 
 
Twenty six per cent of patients were treated for pulmonary tuberculosis (PTB) in this cohort. PTB is 
highly prevalent in the Western Cape and the presence of active disease is an exclusion to 
transplantation until fully treated. The majority of these cases were not culture confirmed, but were 
considered as probable PTB and therefore treated empirically. The higher number of TB cases in the 
non-Kasai group may be due to the effects of chronic illness and poor nutritional status on immune 
function. 
The 37.5% 5-year SNL in this cohort is comparable with figures from Canada (33%) (8), France (40%) 
(2), Switzerland (37% 4-year SNL) (7), Netherlands (42% 4-year SNL) (30) and United Kingdom 
(46%) (10). However, the overall 5-year survival of 56% falls far below those seen internationally, 
which range from 77% in Canada (8) to 90% in the UK (10) and 92% in Switzerland (7). The low 
overall survival rates can be explained by poor access to LT with only 12% of our initial cohort 
undergoing transplantation, as opposed to 40% seen in the BARC (Biliary Atresia Research 
Consortium) cohort reported by Shneider et al (16) and 44% reported by Davenport et al in the UK 
(10).  
A previous study conducted in the surgical department at RCWMCH reviewed 39 children undergoing 
Kasai procedure between January 1975 and January 1985 (32). The mean age of operation was 12.8 
weeks. In the first 4 years of the study no patients established successful bile drainage. Thereafter 
50% of KPs were successful in establishing drainage, however only 20% of these patients remained 
alive at the time of analysis. The current cohort (2003-2013) shows a dramatic improvement in age at 
KP which has decreased from 12.8 weeks to 68 days as well as in overall survival.  
 
Delayed presentation and late referral remain a major challenge in the management of BA. Efforts 
aimed at promoting earlier referral through the creation of biliary atresia awareness at the primary 
health care level play an important role in improving outcomes and survival post Kasai surgery. The 
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most successful strategies have been the stool colour cards established in Taiwan in 2004 and the 
“yellow alert” educational programme in the UK aimed at expediting the referral of jaundiced infants 
(8, 14, 33).  
Since the introduction of stool colour cards in Taiwan, BA has been diagnosed earlier with the 
percentage of patients undergoing Kasai before 60 days improving from 49.4% to 65.7%. Jaundice 
clearance post Kasai has improved from 34.8% to 60.8%, with 5-year jaundice free SNL improving 
from 27.3% to 64.3% (33). As Taiwan has the highest incidence of BA, screening in this population is 
bound to yield positive results. A US study on the cost-effectiveness of a screening programme 
concluded that the use of stool colour cards resulted in lower costs and better outcomes for patients 
with BA (34). 
Differentiating physiological jaundice in the neonate from pathological jaundice is essential to facilitate 
early referral. Pale stools, dark urine and jaundice persisting beyond 14 days of life warrants urgent 
referral for further investigation (including conjugated bilirubin). In the RCWMCH cohort initial stool 
colour was not documented in 20% of patients, a figure which is likely to be higher at primary health 
care facilities. This highlights the need to improve awareness amongst both parents and all health 
care professionals.  Although it is unlikely to be financially feasible to include stool colour cards in the 
current Road to Health Card Booklets, posters should be made available at antenatal services and 
baby clinics as part of an educational campaign. Nursing staff administering 6 week immunisations 
should be encouraged to enquire about stool colour. Although referral at 6 weeks would already be 
considered late, it would still allow for KP to be performed within 60 days and would be an 
improvement on our current age at presentation. Employing an algorithm for the appropriate 
management of conjugated hyperbilirubinaemia at peripheral services would aid in facilitating earlier 
referral. 
This study has confirmed that patients can still benefit from undergoing KP beyond 90 days. In a 
country with limited access to transplantation, KP should still be offered to patients presenting late. 
This will allow a significant proportion (38%) of cases the opportunity for successful KP with improved 
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quality of life, as well as delaying the need for transplantation and immunosuppression and alleviating 
strain on the organ donor system.  
In this study age at KP, degree of fibrosis and complications were not associated with poor outcome 
of KP.  
In conclusion, although overall survival figures still lag behind international data, we have made 
enormous progress over the last 30 years within a limited resource setting. Improved awareness and 





1 Davenport M. Biliary atresia: clinical aspects. Semin Pediatr Surg 2012;21(3):175-84. 
2 Chardot C, Buet C, Serinet MO, et al. Improving outcomes of biliary atresia: French national 
series 1986-2009. J Hepatol 2013;58(6):1209-17. 
3 Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet 2009;374(9702):1704-13. 
4 Bijl EJ, Bharwani KD, Houwen RH, et al. The long-term outcome of the Kasai operation in 
patients with biliary atresia: a systematic review. Neth J Med 2013;71(4):170-3. 
5 Hadzic N, Davenport M, Tizzard S, et al. Long-term survival following Kasai 
portoenterostomy: is chronic liver disease inevitable? J Pediatr Gastroenterol Nutr 
2003;37(4):430-3. 
6 Davenport M, De Ville de Goyet J, Stringer MD, et al. Seamless management of biliary atresia 
in England and Wales (1999-2002). Lancet 2004;363(9418):1354-7. 
7 Wildhaber BE, Majno P, Mayr J, et al. Biliary atresia: Swiss national study, 1994-2004. J 
Pediatr Gastroenterol Nutr 2008;46(3):299-307. 
8 Schreiber RA, Barker CC, Roberts EA, et al. Biliary atresia: the Canadian experience. J 
Pediatr 2007;151(6):659-65, 65.e1. 
9 Davenport M, Caponcelli E, Livesey E, et al. Surgical outcome in biliary atresia: etiology 
affects the influence of age at surgery. Ann Surg 2008;247(4):694-8. 
10 Davenport M, Ong E, Sharif K, et al. Biliary atresia in England and Wales: results of 
centralization and new benchmark. J Pediatr Surg 2011;46(9):1689-94. 
11 Wong KK, Chung PH, Chan IH, et al. Performing Kasai portoenterostomy beyond 60 days of 
life is not necessarily associated with a worse outcome. J Pediatr Gastroenterol Nutr 
2010;51(5):631-4. 
12 Davenport M, Puricelli V, Farrant P, et al. The outcome of the older (> or =100 days) infant 
with biliary atresia. J Pediatr Surg 2004;39(4):575-81. 
13 Nio M, Ohi R, Miyano T, et al. Five- and 10-year survival rates after surgery for biliary atresia: 
a report from the Japanese Biliary Atresia Registry. J Pediatr Surg 2003;38(7):997-1000. 
14 Hsiao CH, Chang MH, Chen HL, et al. Universal screening for biliary atresia using an infant 
stool color card in Taiwan. Hepatology 2008;47(4):1233-40. 
41 
15 Serinet MO, Broue P, Jacquemin E, et al. Management of patients with biliary atresia in 
France: results of a decentralized policy 1986-2002. Hepatology 2006;44(1):75-84. 
16 Shneider BL, Brown MB, Haber B, et al. A multicenter study of the outcome of biliary atresia 
in the United States, 1997 to 2000. J Pediatr 2006;148(4):467-74.e1. 
17 McKiernan PJ, Baker AJ, Kelly DA. The frequency and outcome of biliary atresia in the UK 
and Ireland. Lancet 2000;355(9197):25-9. 
18 McKiernan PJ, Baker AJ, Lloyd C, et al. British paediatric surveillance unit study of biliary 
atresia: outcome at 13 years. J Pediatr Gastroenterol Nutr 2009;48(1):78-81. 
19 Lee WS, Looi LM. Usefulness of a scoring system in the interpretation of histology in neonatal 
cholestasis. World J Gastroenterol 2009;15(42):5326-33. 
20 Spearman CW, McCulloch M, Millar AJ, et al. Liver transplantation at Red Cross War 
Memorial Children's Hospital. S Afr Med J 2006;96:960-3. 
21 Loveland JA, Govender T, Botha J, et al. Paediatric liver transplantation in Johannesburg: 
initial 29 cases and prospects for the future. S Afr Med J 2012;102(4):233-6. 
22 Spearman CW, McCulloch MI. Challenges for paediatric transplantation in Africa. Pediatr 
Transplant 2014;18(7):668-74. 
23 Lee WS, Chai PF, Lim KS, et al. Outcome of biliary atresia in Malaysia: a single-centre study. 
J Paediatr Child Health 2009;45(5):279-85. 
24 Aydogdu S, Ozgenc F, AtIk T, et al. Biliary atresia in Turkish children. Pediatr Int 
2004;46(2):158-61. 
25 Chen G, Zheng S, Sun S, et al. Early surgical outcomes and pathological scoring values of 
older infants (>/= 90 d old) with biliary atresia. J Pediatr Surg 2012;47(12):2184-8. 
26 Schoen BT, Lee H, Sullivan K, et al. The Kasai portoenterostomy: when is it too late? J 
Pediatr Surg 2001;36(1):97-99. 
27 Grizelj R, Vukovic J, Novak M, et al. Biliary atresia: the Croatian experience 1992-2006. Eur J 
Pediatr 2010;169(12):1529-34. 
28 Tiao MM, Chuang JH, Huang LT, et al. Management of biliary atresia: experience in a single 
institute. Chang Gung Med J 2007;30(2):122-7. 
29 Hung PY, Chen CC, Chen WJ, et al. Long-term prognosis of patients with biliary atresia: a 25 
year summary. J Pediatr Gastroenterol Nutr 2006;42(2):190-5. 
42 
30 de Vries W, de Langen ZJ, Groen H, et al. Biliary atresia in the Netherlands: outcome of 
patients diagnosed between 1987 and 2008. J Pediatr 2012;160(4):638-44.e2. 
31 Zhen C, Guoliang Q, Lishuang M, et al. Design and validation of an early scoring system for 
predicting early outcomes of type III biliary atresia after Kasai's operation. Pediatr Surg Int 
2015;31(6):535-42. 
32 Millar AJ, Davies MR, Rode H, et al. Biliary atresia--surgical management; A 10-year review. 
S Afr Med J 1986;69(5):288-93. 
33 Lien TH, Chang MH, Wu JF, et al. Effects of the infant stool color card screening program on 
5-year outcome of biliary atresia in Taiwan. Hepatology 2011;53(1):202-8.
34 Mogul D, Zhou M, Intihar P, et al. Cost-effective analysis of screening for biliary atresia with 
the stool color card. J Pediatr Gastroenterol Nutr 2015;60(1):91-8. 
43 
 
Table 1: Cohort characteristics 
 n* (%) 







Median age at presentation 70 
Median age at KP 68 














Ultrasound findings (n=54) 
Consistent with BA 





Consistent with BA 












Age at KP (days) *** 
< 31 (n=5) 
31-60 (n=20) 
61-90 (n=21) 


















* Number of cases with information available 
** Biopsy revealed biliary atresia, with subsequent cholangiogram and KP being performed 
*** 3 cases LTFU immediately post KP, were not included in this analysis 
 
 
Table 2: Frequency of complications (n depicts number of cohort for which information was available) 
 





39.2%  n* = 56 72.2%  n = 18 
Cholangitis  70.1%  
(40.3% recurrent) 









9.8%  n = 51 6.7%  n =15 
TB  
 
26.7% 22.8%  n = 57 38.9%  n = 18 
 






Figure 1: Outcomes of 80 patients with biliary atresia managed at RCWMCH 2003-2013 
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-
Figure 2 Kaplan Meier survival curves: 2a.) Overall, native liver and transplanted liver 







DATA CAPTURE SHEETS 
Index Case Number 
Folder Number 
Age at presentation (days) 
Race  
1 African; 2 Mixed; 3 White; 4 Other 
Sex 
1 Male; 2 Female 
Source of referral 
1 GP; 2 clinic/day hosp; 3 secondary; 4 tertiary; 
5 other 
Number of visits prior to referral 
Date of birth 
Date of presentation 
Date of Kasai 
Date entered transplant list 
Date transplanted 
Date of death 
Presenting features 
Jaundice (0 no; 1 yes) 
Pale stools (0 no, 1 yes) 
Other 
Associated Congenital Abnormalities 
0 = nil; 1 = yes (specify) 
LABORATORY VALUES 
Bili (TB/CB)  
P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 
A1/2/3/4… = annually 
AST 
P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 
A1/2/3/4… = annually 
ALT 
P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 
A1/2/3/4… = annually 
ALP 
P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 




P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 
A1/2/3/4… = annually 
Albumin 
P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 
A1/2/3/4… = annually 
INR 
P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 
A1/2/3/4… = annually 
Hb 
P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 
A1/2/3/4… = annually 
GROWTH PARAMETERS 
Weight (Z scores) 
P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 
A1/2/3/4… = annually 
Height (z scores) 
P = Presentation; K = Kasai; K3 = 3/12 post Kasai; 







Age in days 
Surgeon performing Kasai 
0 = consultant; 1 = registrar 
Pigmented stools 3/12 post Kasai 
0 = no; 1 = yes 
Clearance of jaundice 3/12 Post Kasai 
0 = no; 1 = yes 
COMPLICATIONS POST KASAI 
Ascites 
0 = no; 1 = yes (number of episodes) 
Cholangitis 
0 = no; 1 = yes (number of episodes) 
Varices 
0 = no; 1 = yes (number of episodes) 
Bacterial peritonitis 
0 = no; 1 = yes (number of episodes) 
Growth failure 
0 = no; 1 = yes 
Other (e.g. TB, rickets, specify) 
OUTCOMES 
Successful Kasai 
0 = no, 1 = yes 
Progression to require transplant 
0 = no; 1 = yes 
Transplanted 
0 = no; 1 = yes 
Alive at data collection 
0= no (capture cause of death); 1 = yes; 2 = LTFU; 3 = 
transferred to another centre 
Addendum: 
Race was not captured as it is not recorded in hospital records. 
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HISTOLOGICAL SCORING SYSTEM FOR NEONATAL CHOLESTASIS 
Seven-feature, 15-point histological scoring system devised for the interpretation of liver biopsy 
materials in neonatal cholestasis 
Parameter Histological characterization Histological grade 










< 50% of portal tracts 1 
> 50% of portal tracts 2 






Only around central vein 1 
Diffuse 0 
Neutrophils in the infiltrate 
Absent or mild 1 






The higher the score, the more likely to be biliary atresia. 
 
Citation: Lee WS, Looi LM. Usefulness of a scoring system in the interpretation of 
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We look forward to sharing care of this infant who has Biliary Atresia, and underwent a Kasai 
Portoenterostomy. Biliary drainage is achieved in up to 80% of patients. Subsequently some of these 
children will develop complications of cirrhosis (portal hypertension, liver dysfunction etc.) and will be 
considered for liver transplant electively. Children who do not achieve bile drainage (i.e. remain 
jaundiced) have an unsuccessful Kasai and should be referred for liver transplant. 
 
CONTACT NUMBERS 
Ward D2, GIT Unit on Ward E2 




 2nd, 3rd & 4th week SOPD 
5th  week GIT follow-up in Liver OPD Monday am. 
2 - 3 month GIT Liver clinic 
6 month GIT  Liver clinic 




The following regimen is followed: 
 
Steroids (two week course) 
Initially IV in hospital Methylprednisolone 20mg commencing on POD 1, decreasing 2.5mg daily 
until 5mg/day.  This is then completed at a dose of  5mg orally until POD 14. 
 
Further need for steroids to be assessed in clinic but may be reintroduced as a short course if an 
episode of cholangitis results in sudden cholestasis after good bile drainage. 
 
Antibiotic prophylaxis for 5 days 
From induction IVI  Ampicillin  25mg/kg/dose 6hrly,  Gentamycin  6mg/kg/dose daily (check levels) 





Long term oral antibiotic prophylaxis 
From Day 6 Ciprofloxacin 12.5mg/kg/dose bd for one month then daily for 3 months 
Then a cycle of:   Amoxycillin 25mg/kg once a day for 12 weeks (max of 1 gram) 
Cephalexin 12.5mg/kg once a day for 12 weeks (max of 500 mg) 
 
   Then cycle indefinitely 
 
Vitamin supplements 
The infant will be receiving the following vitamins 
 
Vitamin A (retinol) (started in out patients at first surgical review) 
  Trade Name = Arovit®  
  Presentation  = 150,000 iu/ml (equivalent to 5,000iu/drop)  
<1 year  5000 units/day oral 
     
Vitamin D (alfacalcidol) (started in BCH out patients at first surgical review) 
  Trade Name = One Alpha®   
Presentation = 2mcg/ml (equivalent to 100ng/drop)  
  Neonate + premature 50-100 nanograms/kg/daily oral 
     
Vitamin E (alpha tocopheryl) (started in BCH out patients at first surgical review) 
  Trade Name = Ephynal 
  Presentation = 500mg/5ml suspension 
  <1 year  50mg/day oral 
     
Vitamin K (phytomenadione) (From Day 5 post surgery) give as either 
 Trade Name  =  Menadiol liquid 
 Presentation =  5mg in 5mls 
 Neonate + premature 300 micrograms/kg/day oral 
 
     or 
  Trade Name =  Konakion® MM Paediatric 
  Presentation  =  2mg in 0.2ml  




These should stop at 1 year unless failing to thrive or having significant cholangitis 
See Appendix for details of suppliers and dosages for older children 
 
(iv) Other medication (from day 5 post surgery) 
 
Ursodeoxycholic acid 
5 – 7mg/kg 2-3 times a day Max 45mg/kg/day 
Suspension 250mg in 5ml  
 
Phenobarbitone (alcohol, sugar and colour free) 
3-5mg/kg daily - all ages 
oral liquid 50mg in 5mls  
 
Ranitidine  
2mg/kg tds oral 
Oral liquid 75mg in 5mls 
 
Omeprazole 
1mg/kg/day  oral 
 
Fish oil (empirical dose of 100mg/day for Essential Fatty Acid support) 
  
These will be reviewed periodically and duration of use will depend on the success of the operation, 




Vaccination may start after finishing Prednisolone.  No live vaccines should be given until steroid free 
for 3 months.  These infants should receive Prevenar® (Pneumoccal Conjugate Vaccine) This is a 3 
dose course that can be given alongside the normal immunisations of DtaP/IPV/HIB+Men C. 
Practically to avoid 3 injections given at once time, the Prevenar can be given 2 weeks after each 
dose of DtaP/IPV/HIB+Men C to reduce the number of injections given at one time.  There is a 2 dose 
schedule between 7-11 months with at least 1 month between doses.  A third dose is recommended 
in the second year of life for whatever scheme is used.  They should have Pneumovax II when they 
reach 2 years of age. We recommend a course of Hepatitis B once the primary vaccination course is 
finished. Infants who start their course of Prevenar after 1 year of age should have 2 injections 
separated by 2 months followed by Pneumovax II when they get to 2 years of age. We also 









Fever > 37.3 for 24 hours or if child is unwell and no other obvious cause  (check urine, ENT and 
chest) 
Jaundice/pale stools/abnormal transaminases, rise in ALP/GGT/increased neutrophils 
 
Management 
Septic Screen (including two blood cultures at 1 hour interval, chest x-ray, urine m + c & s) no lumber 
puncture unless indicated. Please discuss with the on call liver unit registrar at this point. 
 
Start IV antibiotics 
Ceftazidime 30mg/kg/dose tds for 10 days 
Ampicillin  50mg/kg/dose tds for 10 days 
(change antibiotic if needed according to culture) 
 
If temperature does not settle after 2 days or returns on discontinuation of antibiotics, start 
CIPROFLOXACIN (10Mg/kg/8hrs) at full dose. Please discuss with on call liver unit registrar at Red 
Cross Hospital. The child may need an ascitic tap and liver biopsy for bacteriological culture and 
further therapy based on the c & s. 
 
The second line treatment is usually 
 
 Meropenem  10-20mg/kg  tds 
 Vancomycin  10mg/kg tds 
    15/kg loading dose (levels 4th dose) 
 
Lab tests 
Monitor full blood count and liver function test at least twice a week 
 
Pruritus 
This can be present in unsuccessful Kasai.  If the baseline treatment of Ursodeoxycholic acid dose 
and Phenobarbitone dose is not adequate at their maximum doses the following can be tried up to 




In general a single drug should be used with a stepwise dose increase till effective or maximum dose 
reached.  Combination treatment should be avoided 
Rifampicin 
3-10mg/kg once a day liquid 100mg in 5ml Rifadin® available 
 
Cholestryramine 
Under 6 years    2g (½ sachet) day Over 6 4g (1sachet) day 
Questran Light® 4g/sachet Increase dose according to response 
Give as single dose or in up to 4 divided doses Other drugs especially vitamins should be given 1 
hour before or 6 hours after 
 
Odansetron 
2-4mg bd up to 12 years of age then 4-8mg 12-18 year. Solution Zofran® 4mg in 5ml available 
 
 
      Professor Alastair J.W. Millar  
 
              
APPENDIX                                                      
VITAMIN REGIMEN 
 
VITAMIN A (RETINOL) 
  Trade name = Arovit®  (unlicensed) 
  Formulation = Solution 
  Presentation  = 150,000 iu/ml (equivalent to 5,000iu/drop) 
  Supplier = Idis Ltd (Tel: 0208 4100710) 
 
<1 year 5000 units/day 
    >1 year up to 10,000 units/day 
 
VITAMIN D (ALFACALCIDOL) 
  Trade name = Dependent on presentation 
  Formulation = Solution and capsules 
  Presentation = 1mcg capsules – One Alpha® 
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     0.25mcg capsules – Alfa D 
     2mcg/ml drops – One Alpha®(equivalent to 100ng/drop)  
  Supplier = Wholesalers (e.g. AAH)   
 
Neonate + premature 50-100 nanograms/kg/daily 
    Up to 20kg   25 – 50 nanograms/kg daily 
    Over 20kg   1 microgram/day 
    Up to 2 micrograms in severe cases 
 
VITAMIN E (ALPHA TOCOPHERYL) 
  Trade Name = Ephynal 
  Formulation = Suspension and tablets 
  Presentation = 500mg/5ml suspension 
     50mg and 200mg tablets  
  Supplier = Wholesalers (e.g. AHH) 
 
    <1 year 50mg/day 
    >1 year 100 – 200mg/day 
    12- 18 months 200mg/day 
 
 
VITAMIN K (PHYTOMENADIONE)  
  Trade Name = Konakion®MM Paediatric 
  Formulation = Injection (for IV and oral use) (Mixed micelles) 
     (Menadiol is the preferred formulation for oral use) 
  Presentation  = 2mg in 0.2ml  
  Supplier = Wholesalers (e.g. AHH) 
  Trade Name = Menadiol 
  Formulation = Tablets   Liquid (unlicensed) 
  Presentation = 10mg and 5mg/5ml 
  Supplier = Wholesalers Boots contract manufacturing  
(e.g. AAH) (ex-specials) 
 
1 – 5 mg/day 
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    Maximum 10mg/day 
    Based on 300 micrograms/kg/day 
 
Vitamins A and E levels are monitored in Red Cross Hospital.                
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The Journal of Pediatric Gastroenterology and Nutrition publishes original articles, special reports, 
review articles, rapid communications, case reports, letters to the editor, short communications, 
and commentaries on all aspects of pediatric gastroenterology, hepatology, pancreatology, and 
nutrition. 
The journal follows the International Committee of Medical Journal Editors' Uniform Requirements 
for Manuscripts Submitted to Biomedical Journals (URM). Manuscripts must be prepared in 
accordance with the URM (N Engl J Med 1997;336:309-15 and updated at http://www.icmje.org/). 
Manuscripts not prepared according to the Instructions to Authors will be returned to the author(s) 
without review. 
ETHICAL AND LEGAL CONSIDERATIONS 
A submitted manuscript must be an original contribution not previously published (except as an 
abstract), must not be under consideration for publication elsewhere, and, if accepted, it must not 
be published elsewhere in similar form, in any language, without the consent of Wolters Kluwer. 
Each person listed as an author is expected to have participated in the study to a significant 
extent. Although the editors and reviewers make every effort to ensure the validity of published 
manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the 
publisher. 
 
Documented review and approval from a formally constituted review board (Institutional Review 
Board or Ethics committee) is required for all studies involving people, medical records, and 
human tissues, and for all animal studies. For authors/investigators that do not have access to 
formal ethics review committees, the principles outlined in the Declaration of Helsinki should be 
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followed. If the study is judged exempt from review, a statement from the committee should be 
provided. Informed consent by participants should always be sought. If not possible, an 
institutional review board must decide if this is ethically acceptable. 
Plagiarism detection 
JPGN is a member of CrossCheck by CrossRef and iThenticate. iThenticate is a plagiarism 
screening service that verifies the originality of content submitted before publication. iThenticate 
checks submissions against millions of published research papers, and billions of web content. 
Authors, researchers and freelancers can also use iThenticate to screen their work before 
submission by visiting www.ithenticate.com. 
Declaration of Funding Source 
ACKNOWLEDGMENT OF GRANTS OR FINANCIAL SUPPORT MUST BE DECLARED FOR ALL 
MANUSCRIPTS. In addition, authors of all articles in which the effect of a drug, appliance, or 
treatment is evaluated must also acknowledge all support from the manufacturer of such drug, 
appliance, or treatment or its competitor. Authors of review articles, editorials, letters to the 
editor, and other commentaries must disclose any financial interests that might have an impact on 
the views expressed in the article, editorial, letter, or commentary. The Declaration of Funding 
Source statement will be included in the published article or commentary. 
 
The conflict of interest disclosure and funding declaration must be included on the title page of the 
manuscript and in Editorial Manager. Authors with nothing to declare should provide a statement 
to that effect. Manuscripts submitted without the required disclosures will be returned to the 
authors. 
Compliance with NIH and Other Research Funding Agency Accessibility Requirements 
A number of research funding agencies now require or request authors to submit the post-print 
(the article after peer review and acceptance but not the final published article) to a repository 
that is accessible online by all without charge. As a service to our authors, Wolters Kluwer will 
identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the 
post-print of an article based on research funded in whole or in part by the National Institutes of 
Health, Wellcome Trust, Howard Hughes Medical Institute, or other funding agencies to PubMed 
Central. The Copyright Transfer Agreement provides the mechanism. 
Patient anonymity and informed consent 
It is the author's responsibility to ensure that a patient's anonymity be carefully protected and to 
verify that any experimental investigation with human subjects reported in the manuscript was 
performed with informed consent and following all the guidelines for experimental investigation 
with human subjects required by the institution(s) with which all the authors are affiliated. 
 
Authors should remove patients' names and other identifying information from figures. If any 
identifying details appear in text, tables, and/or figures, the author must provide proof of informed 
consent obtained from the patient (i.e., a signed permissions form). Photographs with bars placed 
over eyes of patients should NOT be used in publication. If they are used, permission from the 
patient is required. 
 
The corresponding author of a Case Report must provide the editorial office at the time of 
submission of the manuscript a written guarantee indicating that the subject(s) of the case report 
or their parents (or guardians) are aware of the intent to publish and agree to it. 
 
If the parents or guardian were unable to be located for their consent, a signed statement from 
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the Chair of the Department may be accepted. The statement must read: all attempts have been 
exhausted in trying to contact the parents or guardian for the purpose of attaining their consent to 
publish the Case Report. 
Conflicts of Interest 
Authors must state all possible conflicts of interest in the manuscript, including financial, 
consultant, institutional and other relationships that might lead to bias or a conflict of interest. If 
there is no conflict of interest, this should also be explicitly stated as none declared. All sources of 
funding should be acknowledged in the manuscript. All relevant conflicts of interest and sources of 
funding should be included on the title page of the manuscript with the heading "Conflicts of 
Interest and Source of Funding:" For example: 
Conflicts of Interest and Source of Funding - A has received honoraria from Company Z. B is 
currently receiving a grant (#12345) from Organization Y, and is on the speaker's bureau for 
Organization X – the CME organizers for Company A. For the remaining authors, none are 
declared. 
Copyright 
In addition, each author must complete and submit the journal's copyright transfer agreement, 
which includes a section on the disclosure of potential conflicts of interest based on the 
recommendations of the International Committee of Medical Journal Editors, "Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals" (www.icmje.org/update.html). 
A copy of the form is made available to the submitting author within the Editorial 
Manager submission process. Co-authors will automatically receive an e-mail with 
instructions on completing the form upon submission. 
Please note that only activities presenting a possible conflict of interest with the work submitted 
must be disclosed. 
Permissions 
Authors must submit written permission from the copyright owner (usually the publisher) to use 
direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along 
with complete details about the source. Any permissions fees that might be required by the 
copyright owner are the responsibility of the authors requesting use of the borrowed material, not 
the responsibility of Wolters Kluwer. 
Drugs, Devices, and Other Products 
Use nonproprietary names of drugs, devices, and other products, unless the specific trade name is 
essential to the discussion. The trade name may appear once in the Abstract and once in the 
Introduction or Methods section, followed by the nonproprietary name, manufacturer, and 
manufacturer location in parentheses; all other mention of the product must use the generic 
name. Trade names of drugs and other products must not appear in the article title. 
MANUSCRIPT SUBMISSION 
Clicking on the submission service link on this page will open our manuscript submission service 
website in a new browser window. 
 
Submit a manuscript 
First-time Users 
Please click the Register button in the main menu and enter the requested information. Upon 
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successful registration, you will be sent an email indicating your user name and password. Save a 
copy of this information for future reference. Note: If you have received an email from us with an 
assigned user ID and password, or if you are a repeat user, do not register again. Once you have 
an assigned ID and password, you do not have to re-register, even if your role changes (that is, 
author, reviewer, or editor). Authors please click the login button from the menu at the top of the 
page and log in to the system as an Author. Submit your manuscript according to the author 
instructions. You will be able to track the progress of your manuscript through the system. If you 
experience any problems, please contact the appropriate Editorial Office (see below for complete 
contact information) or click on the 'Contact Us' link in the header menu. 
ARTICLE TYPES 
Rapid Communication: This article type allows for rapid review (within 10 days) and publication 
of original studies. Manuscripts considered for rapid review will be limited to reports judged to be 
of general scientific or public health importance. Authors submitting Rapid Communications must 
provide a detailed cover letter outlining the rationale for fast tracking their work. Authors must 
state whether the findings could alter current standards of patient care (e.g., finding efficacy or 
lack of efficacy of treatment), and/or if the findings suggest a novel mechanism or understanding 
of disease process (e.g., new susceptibility gene identification in H pylori organism). 
 
Rapid Communications should contain no more than 3000 words, structured abstract with no more 
than 250 words and no more than four figures and tables combined (for example, a submission 
may include 4 figures, 1 figure and 3 tables, 4 tables, etc., but not 2 figures and 3 tables) and no 
more than 50 references. Submissions exceeding these parameters without justification or without 
a detailed cover letter explaining the rationale for a Rapid Communication will be returned to the 
author for correction prior to review. 
Original Articles: Original articles are full-length reports of original research. Original articles are 
accepted based on their scientific relevance, the originality of the work, and the priority of the 
work for JPGN and its readership. Authors should aim for accuracy, clarity, and brevity. Long 
introductions, repetition of data among tables, figures, and the text, and unfocused discussions 
should be avoided. 
Original research articles should be approximately 18 double-spaced, numbered pages, including 
the title page, references, figures, and tables. Failure to comply with length restrictions may result 
in a delay in the processing of your paper. The following length targets are recommended for 
Original Articles: 
 Structured Abstract: maximum of 250 words 
 Introduction: 1 page 
 Methods: 2-3 pages 
 Results: 2-3 pages 
 Discussion: 3-5 pages 
 References: limited to those critical and relevant to the manuscript (not more than 50) 
 Tables and Figures: 4 total 
 Additional/supplemental content may be submitted as "Supplemental Digital Content 
(SDC)" 
Clinical Trials: Clinical trials are Original Articles of studies that prospectively assign human 
subjects to specific intervention or comparison groups and determine the relationship between an 
intervention and outcome. To ensure consistency with the guidelines of the Clinical Trial 
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Registration Statement from the International Committee of Medical Journal Editors 
(http://content.nejm.org/cgi/content/full/NEJMe078110), all trials submitted to the Journal with 
patient enrollment commencing after January 1, 2009 must be registered in a public trials registry 
prior to enrollment of the first subject. The registry must incorporate free public access, and must 
be searchable, open to prospective registrants, and have not-for-profit management. The following 
information must be included in the registry: (1) unique identifying number, (2) statement of 
intervention(s), (3) hypothesis, definition of primary and secondary outcome measurements, 
eligibility criteria, target number of subjects, funding source, contact information for principal 
investigator, and dates of registration, start and completion. Authors should provide the URL 
(website address) and trial identification number on the title page of the manuscript. This 
information will be published with the article. Structured Abstract (no more than 250 words). No 
more than 50 references permitted. Clinical trial reports should comply with the Consolidated 
Standards of Reporting Trials (CONSORT) (www.consort-statement.org). 
Review Articles: Review articles are usually solicited by the Editorial Board. However, unsolicited 
reviews of exceptional interest will also be considered. Authors should contact the Editors before 
submitting a review to determine whether the topic and contents are appropriate for JPGN. All 
proposed reviews will be approved based on a submitted list of author(s) and a brief outline for the 
proposed review. Reviews should be balanced and unbiased. Review articles undergo peer review. 
Please include an unstructured abstract (no more than 250 words). For Systematic reviews/Meta-
analyses structured reviews (no more than 250 words). 
Short Communications: This category comprises brief reports on topics relevant to the JPGN 
reader and preliminary reports of original studies of relevant scientific importance. Short 
Communications must not exceed 8 manuscript pages including tables and references (calculated 
at 250 words per page, and including figures, where two figures equal one typed page). Include an 
unstructured abstract of 150 words or less. No more than 50 references permitted (included in the 
page count). 
Invited Commentary: These submissions are typically no more than 500-1000 words in length 
and are usually considered by invitation only. Requests to submit a commentary regarding a 'hot 
topic' should be made to one of the editors. Generally no more than 5-10 references, and 1 table 
and/or 1 figure are permitted. No abstract needed. 
Topic of the Month: These submissions are typically no more than 1000-1500 words in length 
and are usually considered by invitation only. Unstructured abstract no more than 150 words. 
References should be limited to those critical and relevant to the manuscript. No more than 30 
references and a total of 2 figures and/or tables. 
Societal Papers: These submissions are coordinated by ESPGHAN and/or NASPGHAN. For more 
information about submitting a societal paper, please contact the ESPGHAN or NASPGHAN 
Consulting Editor for Societal Papers. Abstract optional, no more than 250 words, can be 
structured or unstructured. 
Online Only Article Types 
Please Note: Case Reports, Image of the Month, Video of the Month, and Letters to the Editor will 
be reviewed and accepted as online only content. Papers in these sections will still be assigned to 
an issue and listed in the issue's Table of Contents, and will appear in full on the journal website 
and in all electronic versions of the journal. 
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Case Reports (online only): As of October 1, 2014, JPGN has temporarily suspended the 
submission of new Case Reports until further notice. Rare exception will be made for unique 
cases that are deemed important to the health of our patients or the advancement of the 
knowledge base in our field. If you wish to submit a Case Report under this condition, please e-
mail a brief paragraph that explains why your case meets the above criteria to the applicable 
Editorial Office. Alternately, you may submit your report as a Letter to Editor. Please review 
submission parameters for Letters may include up to one figure or table. 
Case Reports will be considered for publication only if they concern a hitherto unrecognized 
condition or offer new insight into the pathophysiology, diagnosis, or treatment of a disease. 
Patients should always be referred to as "the patient"; initials or other identification should not be 
used. Case Reports must not exceed 1,000 words, and may include up to three tables and figures, 
and no more than 8 references. An abstract is not required, and if present, it will be included in 
the word count. 
Image of the Month (online only): Submissions for the "Image of the Month" should include 
one (at most two) high quality TIF endoscopic, histologic, radiologic, or photographic images of 
unusual or informative findings. A brief description of no more than 200 words should accompany 
the images. No more than 8 references permitted. No abstract. 
Video of the Month (online only): Submissions for the "Video of the Month" should include high 
quality endoscopic video of unusual or informative findings. One or two additional associated 
photos, such as radiologic, pathologic, or photographic images, can also be submitted for online 
publication. A brief description of no more than 200 words should accompany the video. No more 
than 8 references permitted. No abstract. Videos should be uploaded as Supplemental Digital 
Content with one of the following file extensions: .wmv, .mov, .qt, .mpg, .mpeg, .mp4; and 
formatted with a 320 x 240 pixel minimum screen size. For more information, please review 
Wolters Kluwer's requirements for submitting supplemental digital 
content: http://links.lww.com/A142. 
Letters to the Editor (online only): A Letter to the Editor may be in response to an article 
published in JPGN or may comment on a controversial issue. Letters should be brief (less than 250 
words), and will be published at the discretion of the editor. No abstract. 
Filler material (in print only): Material such as historical vignettes, photographs, or brief 
poems/stories/comments may be submitted as 'filler' material that are inserted by the publisher 
into extra space as available. "Filler" space is available when a paper does not fill at least 50% of 
the last page in the proofs of the paper. "Fillers" are accepted at the discretion of the Editors in 
Chief. 
MANUSCRIPT PREPARATION
Manuscripts that do not adhere to the preceding guidelines and following instructions will be 
returned to the corresponding author for technical revision before undergoing peer review. 
Concise, clearly written articles are more likely to be accepted for publication in the Journal of 
Pediatric Gastroenterology and Nutrition. Authors whose first language is not English are 
STRONGLY encouraged to ask a native English-speaking colleague or a professional author's 
editor, preferably with knowledge in the subject matter contained in the manuscript, to edit their 




Cover Letter: In the cover letter provide a statement as to whether the paper was previously 
published in any language, including the abstract and whether the paper is currently under 
consideration elsewhere for publication. 
Title page: Include on the title page (a) complete manuscript title; (b) authors' full names, in 
order first name (given name) then last name (family name), highest academic degrees, and 
affiliations; (c) name and address for correspondence, including fax number, telephone number, 
and email address; (d) address for reprints if different from that of corresponding author; (e) all 
sources of support, including pharmaceutical and industry support, that require acknowledgment; 
(f) the URL (website address) and trial identification number; (g) disclosure of funding received for 
this work from any of the following organizations: National Institutes of Health (NIH); Wellcome 
Trust; Howard Hughes Medical Institute (HHMI); and other(s); and (h) the word count of the 
manuscript body (excluding abstract except in Case Reports, keywords, references and figure 
legends), number of figures and number of tables. 
All relevant conflicts of interest and sources of funding must also be included on the title page of 
the manuscript with the heading "Conflicts of Interest and Source of Funding." If there is no 
conflict of interest, this should also be explicitly stated as none declared. 
On a separate page, list each author and his/her respective roles in the submitted work, 
documenting appropriate input for authorship 
(http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-
authors-and-contributors.html#two). 
Title length: The manuscript title should have no more than 120 characters including spaces. 
Keywords for referencing should be included in the title. Please no abbreviations. Fancy or comical 
titles are inappropriate and will be asked to be revised. Trade names of drugs and other products 
must not appear in the article title. 
Structured abstract and key words: Limit the abstract to 250 words. Do not cite references in 
the abstract. Limit the use of abbreviations and acronyms. At first mention, please write out the 
full term for abbreviations (e.g. Celiac Disease (CD)). Use the following subheads in your 
structured abstract: Objectives, Methods, Results, and Conclusions. 
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*PLEASE NOTE: As of October 1, 2014, JPGN has temporarily suspended the submission of new 
Case Reports until further notice. Alternatively you may submit your report as a Letter to Editor. 
Please review submission parameters for Letters. You may include up to one figure or table. 
What is Known/What is New: Immediately following the abstract for all article types except 
where indicated in chart above, authors should include text for a summary box that will be 
published on the first page of all accepted articles. This text should highlight the significance of the 
article with the following guidelines in mind: What is known about this subject? What are the new 
findings and/or what is the impact on clinical practice? Use the format: 
 What is known (2-4 bullet points listed beneath this heading) 
 What is new (2-4 bullet points listed beneath this heading) 
The total text should not exceed 100 words. At first mention of an abbreviation, please write out 
the full term. 
Text: Organize the manuscript into four main headings: Introduction, Methods, Results, and 
Discussion. If a brand name is cited, supply the manufacturer's name and address (city and 
state/country). Under Methods, include ethical approval information, if applicable. 
Data Analysis: Description of data analyses should provide the specific methods used, their 
rationale, their assumptions, whether data met those assumptions, and how any missing data 
were handled. 
 
Abbreviations: For a list of standard abbreviations, consult the Council of Biology Editors Style 
Guide (available from the Council of Science Editors, 9650 Rockville Pike, Bethesda, MD 20814) or 
other standard sources. Write out the full term for each abbreviation at its first use in abstract, 




References: Please adhere to the reference limits noted for each article type above. The authors 
are responsible for the accuracy of the references. Key the references (double-spaced) at the end 
of the manuscript. Cite the references in text in the order of appearance. Cite unpublished data—
such as papers submitted but not yet accepted for publication and personal communications, 
including email communications—in parentheses in the text. If there are more than three authors, 
name only the first three authors and then use et al. Refer to the List of Journals Indexed in Index 




I. Rautava S, Lu L, Nanthakumar NN, et al. TGF-β2 induces maturation of immature human 
intestinal epithelial cells and inhibits inflammatory cytokine responses induced via the NF-κB 
pathway. J Pediatr Gastroenterol Nutr 2012;54:630-8. 
Book chapter 
2. Todd VR. Visual information analysis: frame of reference for visual perception. In: Kramer P, 
Hinojosa J, eds. Frames of Reference for Pediatric Occupational Therapy. Philadelphia: Lippincott 
Williams & Wilkins; 1999:205–56. 
Entire Book 
3. Ming S-C, Goldman H. Pathology of the Gastrointestinal Tract. Philadelphia: Lippincott Williams 
& Wilkins; 1998. 
Software 




5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol [serial 
online] January 1988;71: 22-37. Available from: BRS Information Technologies, McLean, VA. 
Accessed December 15, 1990. 
Database 
6. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 1996. Updated 
March 29, 1996. 
World Wide Web 
7. Sullivan D. Major search engines and directories. SearchEngineWatch Web 
site. http://www.searchenginewatch.com/links/article.php/2156221. Published May 8, 2011. 
Accessed July 13, 2012. 
Figure legends: Each figure must have a legend. Legends should be brief and should be typed on 
a separate manuscript page, directly following the reference list. Use scale markers in the image 
for electron micrographs, and indicate the type of stain used. Please let the editors and reviewers 
know if any of the figures (e.g., figures of study design) are appropriate for the on-line 
supplemental digital content (SDC) rather than needing to be in-print version. 
Figures: 
A) Creating Digital Artwork 
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 Learn about the publication requirements for Digital Artwork: http://links.lww.com/ES/A42 
 Create, Scan and Save your artwork and compare your final figure to the Digital Artwork 
Guideline Checklist (below). 
 Upload each figure to Editorial Manager in conjunction with your manuscript text and 
tables. 
B) Digital Artwork Guideline Checklist 
 Artwork should be saved in TIFF, Word Doc, PPT or EPS format (PDF is not recommended). 
 Artwork is created as the actual size (or slightly larger) it will appear in the journal. (To get 
an idea of the size images should be when they print, study a copy of the journal to which 
you wish to submit. Measure the artwork typically shown and scale your image to match.) 
 Crop out any white or black space surrounding the image. 
 Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution of 
at least 1200 dpi. 
 Photographs, radiographs and other halftone images must be saved at a resolution of at 
least 300 dpi. 
 Photographs and radiographs with text must be saved as postscript or at a resolution of at 
least 600 dpi. 
 Each figure must be saved and submitted as a separate file. Figures should not be 
embedded in the manuscript text file. 
C) Remember: 
 Cite figures consecutively in your manuscript. 
 Number figures in the figure legend in the order in which they are discussed. 
 Upload figures consecutively to the Editorial Manager web site and number figures 
consecutively in the Description box during upload. 
Tables: Cite tables consecutively in the text and number them in that order. Each table should be 
submitted as a separate Word document in text format. Each table must have a title. Use 
footnotes to define abbreviations and for other explanatory detail in a legend below the Tables. 
Tables should be self-explanatory and must supplement, rather than duplicate, the material in the 
text. Please let the editors and reviewers know if any of the tables (e.g., large data tables) are 
appropriate for the on-line supplemental digital content (SDC) rather than needing to be in-print 
version. 
Supplemental Digital Content (SDC): Authors may submit supplemental digital content to 
enhance their article's text and to be considered for online-only posting. Supplemental digital 
content may include the following types of content: text documents, graphs, tables, figures, 
graphics, illustrations, audio, and video. Cite all supplemental digital content consecutively in the 
text. Citations should include the type of material submitted, should be clearly labeled as 
"Supplemental Digital Content," should include a sequential number, and should provide a brief 
description of the supplemental content. Provide a legend of supplemental digital content at the 
end of the text, listing captions in the order in which the material is cited in the text. The legends 
must be numbered to match the citations from the text. Include a title and a brief summary of the 
content. For audio and video files, also include the author name, videographer, participants, length 
(minutes), and size (MB). No patient-identifying information should be used in supplemental digital 
content unless written consent from the patient, the patient's parents or the patient's guardian has 
70 
 
been obtained. Documentation regarding this consent must be submitted with the manuscript. 
Copyright and Permission forms for article content including supplemental digital content must be 
provided at the time of submission. 
Supplemental Digital Content Size & File Type Requirements: To ensure a quality experience 
for those viewing supplemental digital content, it is suggested that authors submit supplemental 
digital files no larger than 10 MB each. Documents, graphs, and tables may be presented in any 
format. Figures, graphics, and illustrations should be submitted with the following file extensions: 
.tif, .eps, .ppt, .jpg, .pdf, .gif. Audio files should be submitted with the following file extensions: 
.mp3, .wma. Video files should be submitted with the following file extensions: .wmv, .mov, .qt, 
.mpg, .mpeg, .mp4. Video files should also be formatted with a 320 X 240 pixel minimum screen 
size. For more information, please review Wolters Kluwer's requirements for submitting 
supplemental digital content: http://links.lww.com/A142. 
Reviewers: The JPGN editors encourage authors to submit names, departments, institutions, and 
e-mail addresses of 3-7 potential reviewers with appropriate expertise to evaluate the manuscript. 
These potential reviewers should be outside all authors' institution(s) and have no known potential 
conflicts of interest. Names of persons who should not be asked to review the manuscript due to 
potential conflicts of interest should also be submitted. Final choice of reviewers, however, remains 
with the editors. 
OPEN ACCESS 
Wolters Kluwer's hybrid open access option is offered to authors whose articles have been 
accepted for publication. With this choice, articles are made freely available online immediately 
upon publication. Authors may take advantage of the open access option at the point of 
acceptance to ensure that this choice has no influence on the peer review and acceptance process. 
These articles are subject to the journal's standard peer-review process and will be accepted or 
rejected based on their own merit. 
 
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for Journal of Pediatric Gastroenterology and Nutrition is 
$3,000. The article processing charge for authors funded by the Research Councils UK (RCUK) is 
$3,800. The publication fee is charged on acceptance of the article and should be paid within 30 
days by credit card by the author, funding agency or institution. Payment must be received in full 
for the article to be published open access. 
 
Please note: There may be a short delay in PAP for open access articles. 
 
Authors retain copyright 
Authors retain their copyright for all articles they opt to publish open access. Authors grant 
Wolters Kluwer a license to publish the article and identify itself as the original publisher. 
 
Creative Commons license 
Articles opting for open access will be freely available to read, download and share from the time 
of publication. Articles are published under the terms of the Creative Commons License 
Attribution-NonCommerical No Derivative 3.0 which allows readers to disseminate and reuse the 
article, as well as share and reuse of the scientific material. It does not permit commercial 





Compliance with NIH, RCUK, Wellcome Trust and other research funding agency 
accessibility requirements 
A number of research funding agencies now require or request authors to submit the post-print 
(the article after peer review and acceptance but not the final published article) to a repository 
that is accessible online by all without charge. As a service to our authors, Wolters Kluwer 
identifies to the National Library of Medicine (NLM) articles that require deposit and transmits the 
post-print of an article based on research funded in whole or in part by the National Institutes of 
Health, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The 
revised Copyright Transfer Agreement provides the mechanism. Wolters Kluwer ensures that 
authors can fully comply with the public access requirements of major funding bodies worldwide. 
Additionally, all authors who choose the open access option will have their final published article 
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